AMRX - Amneal Pharmaceuticals, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
17.88
-0.85 (-4.56%)
As of 12:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close18.73
Open17.70
Bid17.49 x 1400
Ask17.52 x 800
Day's Range17.25 - 18.25
52 Week Range13.47 - 24.48
Volume1,171,179
Avg. Volume1,243,953
Market Cap5.335B
Beta (3Y Monthly)N/A
PE Ratio (TTM)15.30
EPS (TTM)1.17
Earnings DateNov 7, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.54
Trade prices are not sourced from all markets
  • Opioid antidote inventor: We're in the 'next phase of this opioid crisis'
    Yahoo Finance7 days ago

    Opioid antidote inventor: We're in the 'next phase of this opioid crisis'

    "We are now in the next phase of this opioid crisis, where the majority of deaths arise from fentanyl.”

  • Simply Wall St.18 days ago

    Does Amneal Pharmaceuticals Inc’s (NYSE:AMRX) PE Ratio Signal A Buying Opportunity?

    This analysis is intended to introduce important early concepts to people who are starting to invest and want to learn about the link between company’s fundamentals and stock market performance. Read More...

  • Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference
    PR Newswire22 days ago

    Amneal to Present at the Cantor Fitzgerald Global Healthcare Conference

    BRIDGEWATER, N.J. , Sept. 24, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it will present at the Cantor Fitzgerald Global Healthcare Conference in New York, NY , ...

  • Amneal to Report Third Quarter 2018 Results on November 7, 2018
    PR Newswire25 days ago

    Amneal to Report Third Quarter 2018 Results on November 7, 2018

    BRIDGEWATER, N.J., Sept. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) announced today that the Company will release its third quarter 2018 financial results on Wednesday, November 7, 2018, prior to the open of the U.S. financial markets. The financial results and live webcast will be accessible through the Investor Relations section of the Company's Web site at https://investors.amneal.com.

  • Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP
    PR Newswirelast month

    Amneal Announces FDA Approval and Launch of Generic Chlorpromazine Hydrochloride Tablets USP and Approval of Methylergonovine Maleate Tablets USP

    BRIDGEWATER, N.J. , Sept. 12, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received U.S. Food and Drug Administration (FDA) approval on its Abbreviated New Drug ...

  • Amneal to Present at Upcoming Investor Conferences
    PR Newswire2 months ago

    Amneal to Present at Upcoming Investor Conferences

    BRIDGEWATER, N.J. , Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that it plans to participate at the following upcoming investor conferences. Wells Fargo 2018 ...

  • Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches
    PR Newswire2 months ago

    Amneal Announces Partnership with American Regent on Generic Makena® and Progress on its Business Plan with Additional ANDA Approvals and Launches

    BRIDGEWATER, N.J., Aug. 31, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), a specialty pharmaceutical company, today announced a 5-year supply and distribution agreement with American Regent for the only preservative-free generic alternative to Makena® (hydroxyprogesterone caproate injection, USP, 250mg/mL). Under the terms of the agreement, Amneal will distribute a generic version of Makena to retail consortiums while American Regent will market the product in all other channels including hospital and specialty channels.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Lannett and Amneal Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 21, 2018 / Shares of Amneal Pharmaceuticals saw big gains on Monday after announcing a 10-year license and supply agreement with Jerome Stevens Pharmaceuticals. Shares of Lannett Company went the opposite direction, closing down 60% after the company revealed that its distribution agreement with Jerome Stevens Pharmaceuticals wouldn’t be renewed next year. Lannett Company, Inc. was one of the biggest losers in Monday's trading session, closing the day down 60.37%.

  • Here's Why Amneal Pharmaceuticals Inc. Rose as Much as 13.4% Today
    Motley Fool2 months ago

    Here's Why Amneal Pharmaceuticals Inc. Rose as Much as 13.4% Today

    The company snagged a huge supply contract with Jerome Stevens Pharmaceuticals.

  • Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine
    PR Newswire2 months ago

    Amneal Announces 10-Year Licensing and Supply Agreement with Jerome Stevens Pharmaceuticals, Inc. for Levothyroxine

    BRIDGEWATER, N.J. , Aug. 20, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced a 10-year license and supply agreement for Levothyroxine ...

  • EpiPen Shortage 2018: 13 Things for Parents to Know
    InvestorPlace2 months ago

    EpiPen Shortage 2018: 13 Things for Parents to Know

    Here are a few things to know about the EpiPen shortage. The U.S. Food and Drug Administration has confirmed that there is in fact a shortage of EpiPens. The shortage has actually been going on for months, but is only kick up more dust lately as school starts.

  • MarketWatch2 months ago

    FDA approves first rival generic EpiPen, sending Teva shares up 6%

    Shares of the U.S.-listed Teva Pharmaceutical Industries Ltd. (TEVA) surged 6.2% in extremely heavy Thursday afternoon trade after the company's generic version of the EpiPen allergic reaction treatment was approved by the Food and Drug Administration, making it the product's first true generic rival. Teva secured approval for both adult and child-appropriate dose levels of its generic epinephrine autoinjector. Shares of Mylan (MYL) , which sells the EpiPen and a cheaper authorized generic version, slumped 0.5% in heavy trade, while rivals Amneal Pharmaceuticals Inc. (AMRX) and Adamis Pharmaceuticals Corp. (ADMP) had shares drop 3% and 7.5% respectively.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of AMRX.N earnings conference call or presentation 9-Aug-18 12:30pm GMT

    Q2 2018 Amneal Pharmaceuticals Inc Earnings Call

  • Income Investors Should Steer Clear of Amneal Pharmaceuticals Inc (NYSE:AMRX)
    Simply Wall St.2 months ago

    Income Investors Should Steer Clear of Amneal Pharmaceuticals Inc (NYSE:AMRX)

    Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. In the past, Amneal Pharmaceuticals Inc (NYSE:AMRX) has returned anRead More...

  • Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%
    Zacks2 months ago

    Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%

    Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings Estimates
    Zacks2 months ago

    Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings Estimates

    Amneal (AMRX) delivered earnings and revenue surprises of 4.35% and -0.28%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Amneal: 2Q Earnings Snapshot

    On a per-share basis, the Hayward, California-based company said it had a loss of 15 cents. Earnings, adjusted for restructuring costs and non-recurring costs, were 24 cents per share. The results topped ...

  • PR Newswire2 months ago

    Amneal Announces Solid Second Quarter 2018 Financial Results

    ‒ GAAP Net Revenue of $414 Million ; Adjusted Net Revenue of $462 Million on a Combined Company Basis ‒ ‒ GAAP Loss Per Diluted Share of $0.15 ; Adjusted Income Per Share of $0.24 on a Combined Company ...

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Aquinox Pharma and Three More Healthcare Stocks

    Stock Research Monitor: PRGO, RHE, and AMRX LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AQXP sign up now at www.wallstequities.com/registration . On Monday, July 23, 2018, ...

  • 7 Healthcare Stocks That Are Coming to Life
    InvestorPlace3 months ago

    7 Healthcare Stocks That Are Coming to Life

    U.S. equities continue to churn near major technical resistance levels — S&P 500 2,800 and 25,000 on the Dow Jones Industrial Average — as investors digest a heavy serving of headlines.

  • Benzinga3 months ago

    Morgan Stanley Initiates Amneal Pharmaceuticals, Anticipates Outperformance

    Amneal Pharmaceuticals (NYSE: AMRX ) announced Monday the FDA approval of its newest drug, a generic version of Potassium Chloride oral solution. The Analysts Morgan Stanley analyst David Risinger initiated ...

  • PR Newswire3 months ago

    Amneal Announces FDA Approval and Launch of Generic Potassium Chloride Oral Solution

    BRIDGEWATER, N.J. , July 23, 2018 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a specialty pharmaceutical company, today announced it has received U.S. Food and Drug Administration (FDA) ...

  • Reuters3 months ago

    US mergers help bank fees spike to record highs

    The US$8.1bn earned in the first half of this year slightly topped the prior record US$8bn taken in during the second half of last year, setting a new peak, according to Freeman Consulting Services. The lending pace escalated in the second quarter and is seen staying heated through year-end, encouraged by lower US corporate tax rates and a federal judge’s June endorsement of the long-pursued mega-merger between AT&T and Time Warner. “The market was firing on all cylinders in the second quarter,” said Jeff Nassof, a director at Freeman Consulting.

  • PR Newswire4 months ago

    Amneal to Report Second Quarter 2018 Results on August 9, 2018

    BRIDGEWATER, N.J. , June 29, 2018 /PRNewswire/ --  Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2018 financial results on Thursday, August ...

  • PR Newswire4 months ago

    Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray

    BRIDGEWATER, N.J., June 29, 2018 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 2017 ruling of Judge Richard G. Andrews of the U.S. District Court, District of Delaware, that Lannett Holdings, Inc. and Lannett Company, Inc. (the "Defendants") failed to prove that the U.S. patents 6,750,237 and 7,220,767 protecting Zomig® (zolmitriptan) Nasal Spray were invalid. As previously announced, Amneal's subsidiary, Impax Laboratories, Inc., and, AstraZeneca UK, and AstraZeneca AB, brought suit and had prevailed in the Delaware District Court case against Defendants for patent infringement based on the filing of the Defendants' Abbreviated New Drug Application relating to Zolmitriptan Nasal Spray, 5mg, generic to Zomig Nasal Spray.